Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulism Toxin for Hailey-Hailey or Darier Disease
NCT02782702Phase 1Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2015
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neuronox in Hailey-Hailey disease (HHD) and Darier disease, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Dermatology Life Quality Index at 30 days. Started Sep 2015; status: completed.
02
Drugs
neuronox
03
Conditions
Hailey-Hailey disease (HHD)Darier disease
Beyond the preview
Go deeper on NCT02782702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782702.